Antares launches needle-free injection
Antares Pharma has begun sales of recombinant human insulin along with its Medi-Jector VISION needle-free injection device in India under the trade name Recojet.
India has the largest number of patients with diabetes of any country in the world, with more than 30 million patients already diagnosed and the number of cases expected to grow to approximately 57 million by 2025.
According to Jack Stover, president and ceo of Antares Pharma, the product will help to eliminate the use of approximately 1,000 needles per patient per year, each of which has to be disposed of in a country where there is limited infrastructure to do so safely.
The company currently distributes its needle-free injector systems in more than 20 countries and markets the same technology for use with human growth hormone through licensees in most major regions of the world.